Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Phathom Pharmaceuticals to post earnings of ($1.06) per share and revenue of $27.91 million for the quarter.
Phathom Pharmaceuticals Stock Performance
Shares of Phathom Pharmaceuticals stock traded up $0.04 during trading hours on Monday, hitting $4.15. The company's stock had a trading volume of 841,970 shares, compared to its average volume of 1,025,336. The stock has a market cap of $288.99 million, a price-to-earnings ratio of -0.73 and a beta of 0.35. Phathom Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $19.71. The firm has a fifty day moving average of $5.14 and a 200-day moving average of $8.12.
Wall Street Analyst Weigh In
PHAT has been the subject of a number of research analyst reports. Craig Hallum restated a "buy" rating on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. Cantor Fitzgerald raised Phathom Pharmaceuticals to a "strong-buy" rating in a research report on Tuesday, February 25th. Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. Finally, Guggenheim reiterated a "buy" rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, April 2nd. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $21.83.
Get Our Latest Stock Report on PHAT
About Phathom Pharmaceuticals
(
Get Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Read More
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
